Bullfrog AI Holdings, Inc.
NASDAQ:BFRG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Bullfrog AI Holdings, Inc.
Cash from Financing Activities
Bullfrog AI Holdings, Inc.
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Bullfrog AI Holdings, Inc.
NASDAQ:BFRG
|
Cash from Financing Activities
$2.4m
|
CAGR 3-Years
35%
|
CAGR 5-Years
62%
|
CAGR 10-Years
N/A
|
|
|
Veeva Systems Inc
NYSE:VEEV
|
Cash from Financing Activities
-$9.3m
|
CAGR 3-Years
22%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Inspire Medical Systems Inc
NYSE:INSP
|
Cash from Financing Activities
-$183.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Doximity Inc
NYSE:DOCS
|
Cash from Financing Activities
-$131.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Omnicell Inc
NASDAQ:OMCL
|
Cash from Financing Activities
-$218.3m
|
CAGR 3-Years
-118%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-20%
|
|
|
W
|
Waystar Holding Corp
NASDAQ:WAY
|
Cash from Financing Activities
$243.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bullfrog AI Holdings, Inc.
Glance View
BullFrog AI Holdings, Inc. is a digital biopharmaceutical company, which engages in artificial intelligence and machine learning driven analysis of complex data sets in medicine and healthcare. The company is headquartered in Gaithersburg, Maryland and currently employs 2 full-time employees. The company went IPO on 2023-02-14. The firm is focused on advanced artificial intelligence/machine learning (AI/ML)-driven analysis of complex data sets in medicine and healthcare. Its platform technology, bfLEAP, is an analytical AI/ML platform, which is a potentially disruptive tool for analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational R&D and clinical trial settings. The platform can capture the genetic and physical characteristics of patients in an unbiased manner and contextualize it against other disparate data sources from patients. The Company’s therapeutic pipeline includes siRNA and Mebendazole. Its siRNA targeting Beta2-spectrin in the treatment of human diseases, such as hepatocellular carcinoma (HCC), treatment of obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. Mebendazole is focused on targeting Glioblastoma.
See Also
What is Bullfrog AI Holdings, Inc.'s Cash from Financing Activities?
Cash from Financing Activities
2.4m
USD
Based on the financial report for Dec 31, 2025, Bullfrog AI Holdings, Inc.'s Cash from Financing Activities amounts to 2.4m USD.
What is Bullfrog AI Holdings, Inc.'s Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
62%
Over the last year, the Cash from Financing Activities growth was -72%. The average annual Cash from Financing Activities growth rates for Bullfrog AI Holdings, Inc. have been 35% over the past three years , 62% over the past five years .
